Home › Cempra, Inc. Receives U.S. Orphan Drug Designation For Taksta For Treatment Of Prosthetic Joint Infections
 

Keywords :   


Cempra, Inc. Receives U.S. Orphan Drug Designation For Taksta For Treatment Of Prosthetic Joint Infections

2013-10-30 05:42:32| drugdiscoveryonline News Articles

Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its drug candidate Taksta™ (CEM-102) for the treatment of prosthetic joint infections (PJI)

Tags: treatment drug joint receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11NI rise hits workers harder than employers, says OBR
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 8
05.11Tropical Storm Rafael Public Advisory Number 8
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 8
05.11Lenzing Expands Nonwovens Range
05.11Netflix Europe offices raided in tax fraud probe
More »